A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-07 and is reviewed periodically as new material appears.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
=== set-sez === setastine (INN) setazindol (INN) Sethotope setileuton (USAN, INN) setipafant (INN) setipiprant (INN) setiptiline (INN) setoperone (INN) setrobuvir (USAN) sevabertinib (USAN, INN) sevelamer (INN) sevirumab (INN) sevitropium mesilate (INN) sevoflurane (INN) sevopramide (INN) Sevorane Sevorane AF sezolamide (INN)
Routine blood tests often discover anemia. A sufficiently low hemoglobin by definition makes the diagnosis of anemia, and a low hematocrit value is also characteristic of anemia. Further studies will be undertaken to determine the cause of anemia. If the anemia is due to iron deficiency, one of the first abnormal values to be noted on a complete blood count, as the body's iron stores begin to be depleted, will be a high red blood cell distribution width, reflecting an increased variability in the size of red blood cells. A low mean corpuscular volume also appears during the course of body iron depletion. It indicates a high number of abnormally small red blood cells. A low mean corpuscular volume, a low mean corpuscular hemoglobin or mean corpuscular hemoglobin concentration, and the corresponding appearance of red blood cells on visual examination of a peripheral blood smear narrows the problem to a microcytic anemia (literally, a small red blood cell anemia). The blood smear of a person with iron-deficiency anemia shows many hypochromic (pale, relatively colorless) and small red blood cells. It may also show poikilocytosis (variation in shape) and anisocytosis (variation in size). With more severe iron-deficiency anemia, the peripheral blood smear may show hypochromic, pencil-shaped cells and, occasionally, small numbers of nucleated red blood cells. The platelet count may be slightly above the high limit of normal in iron-deficiency anemia (termed a mild thrombocytosis), but severe cases can present with thrombocytopenia (low platelet count).
==== CIA assessment ==== At the latest, the successful start of Sputnik 2 with the satellite weighing more than 500 kg proved that the USSR had achieved a leading advantage in rocket technology. The CIA, initially astonished, estimated the launch weight of the rocket at 500 metric tons, requiring an initial thrust exceeding 1,000 tons, and assumed the use of a three-stage rocket. In a classified report, the agency described the event as a "stupendous scientific achievement" and concluded that the USSR had likely perfected an intercontinental ballistic missile (ICBM) capable of accurately targeting any location. In reality, the launch weight of the Soviet rocket was 267 metric tons with an initial thrust of 410 tons with one and a half stages. The CIA's misjudgement was caused by extrapolating the parameters of the US Atlas rocket developed at the same time (launch weight 82 tons, initial thrust 135 tons, maximum payload of 70 kg for low Earth orbit). In part, the favourable data of the Soviet launcher was based on concepts proposed by the German rocket scientists headed by Helmut Gröttrup on Gorodomlya Island, such as, among other things, the rigorous weight saving, the control of the residual fuel quantities and a reduced thrust to weight relation of 1.4 instead of usual factor 2. The CIA had heard about such details already in January 1954 when it interrogated Göttrup after his return from the USSR but did not take him seriously.
Military tension between the two countries in the Kargil district led to the Kargil War of 1999, and turmoil in civil-military relations allowed General Pervez Musharraf to take over through a bloodless coup d'état. Musharraf governed Pakistan as chief executive from 1999 to 2002 and as president from 2001 to 2008—a period of enlightenment, social liberalism, extensive economic reforms, and direct involvement in the US-led war on terrorism. By its own financial calculations, Pakistan's involvement in the war on terrorism has cost up to $118 billion, over eighty one thousand casualties, and more than 1.8 million displaced civilians. The National Assembly historically completed its first full five-year term on 15 November 2007. After the assassination of Benazir Bhutto in 2007, the PPP secured the most votes in the elections of 2008, appointing party member Yusuf Raza Gilani as Prime Minister. Threatened with impeachment, President Musharraf resigned on 18 August 2008, and was succeeded by Asif Ali Zardari. Clashes with the judicature prompted Gilani's disqualification from the Parliament and as the prime minister in June 2012. The general election held in 2013 saw the PML (N) achieve victory, following which Nawaz Sharif was elected as Prime Minister for the third time. In 2018, PTI won the general election and Imran Khan became the 22nd Prime Minister. In April 2022, Shehbaz Sharif was elected as prime minister, after Imran Khan lost a no-confidence vote.
== Research == Lebrikizumab is under investigation as an immunosuppressive medication for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. It was created by Tanox under the code name TNX-650, and a phase I clinical trial for refractory Hodgkin's lymphoma had been performed when Genentech acquired Tanox in 2007. It has successfully completed a phase II clinical trial for the treatment of asthma.
Sources: en.wikipedia.org
=== Experimental system === Edward George Bowen joined the team after responding to a newspaper advertisement looking for a radio expert. Bowen had previously worked on ionosphere studies under Appleton, and was well acquainted with the basic concepts. He had also used the RRS' RDF systems at Appleton's request and was known to the RRS staff. After a breezy interview, Watson-Watt and Jock Herd stated the job was his if he could sing the Welsh national anthem. He agreed, but only if they would sing the Scottish one in return. They declined, and gave him the job. Starting with the BBC transmitter electronics, but using a new transmitter valve from the Navy, Bowen produced a system that transmitted a 25 kW signal at 6 MHz (50 metre wavelength), sending out 25 μs long pulses 25 times a second. Meanwhile, Wilkins and L.H. Bainbridge-Bell built a receiver based on electronics from Ferranti and one of the RRS CRTs. They decided not to assemble the system at the RRS for secrecy reasons. The team, now consisting of three scientific officers and six assistants, began moving the equipment to Orfordness on 13 May 1935. The receiver and transmitter were set up in old huts left over from World War I artillery experiments, the transmitter antenna was a single dipole strung horizontally between two 75 foot (23 m) poles, and the receiver a similar arrangement of two crossed wires. The system showed little success against aircraft, although echoes from the ionosphere as far as 1,000 miles away were noted.
=== TLR signaling === As of 2006, the premise that TLR signaling acts as the key node in antigen-mediated inflammatory responses has been in question as researchers have observed antigen-mediated inflammatory responses in leukocytes in the absence of TLR signaling. One researcher found that in the absence of MyD88 and Trif (essential adapter proteins in TLR signaling), they were still able to induce inflammatory responses, increase T cell activation and generate greater B cell abundancy using conventional adjuvants (alum, Freund's complete adjuvant, Freund's incomplete adjuvant, and monophosphoryl-lipid A/trehalose dicorynomycolate (Ribi's adjuvant)). These observations suggest that although TLR activation can lead to increases in antibody responses, TLR activation is not required to induce enhanced innate and adaptive responses to antigens. Investigating the mechanisms which underlie TLR signaling has been significant in understanding why adjuvants used during vaccinations are so important in augmenting adaptive immune responses to specific antigens. However, with the knowledge that TLR activation is not required for the immune-enhancing effects caused by common adjuvants, we can conclude that there are, in all likelihood, other receptors besides TLRs that have not yet been characterized, opening the door to future research.
== Initial investigations == Concerns about an increase in infant collapses and deaths in the neonatal unit at the Countess of Chester Hospital first arose in June 2015, when four collapses occurred, three of them fatal. The unit normally recorded two or three deaths a year. The unit manager, Eirian Powell, and unit lead clinician Brearey carried out an informal review and reported the incidents to the trust's serious‑incident committee, which classified the deaths as medication errors. Brearey noted that Letby had been on duty for each incident but regarded this as an unsurprising coincidence, given staffing levels. He later told the statutory inquiry that no concerns had been raised about her practice at the time. Subsequent reporting in 2023 indicated that he had developed suspicions earlier and believed the trust failed to act on them. A Care Quality Commission inspection in February 2016 heard concerns about difficulties raising issues with managers but was not informed of an elevated mortality rate. Its report highlighted staffing and skill‑mix problems but described a generally positive organisational culture. In May 2016, the trust's executive team concluded that the rise in deaths was coincidental. National MBRRACE‑UK data later showed that the unit's neonatal death rate between June 2015 and June 2016 was at least 10 per cent higher than expected, with deaths in 2015 double those of the previous year. On 24 June 2016, following two further deaths, Brearey asked the duty executive to remove Letby from clinical duties, but was told she was safe to work.
== Further reading == Gessel, Van C. Three Modern Novelists: Sōseki, Tanizaki, Kawabata. New York: Kodansha International, 1993. Ito, Ken Kenneth. Visions of Desire: Tanizaki’s Fictional Worlds. Stanford: Stanford University Press, 1991. Keene, Donald. Dawn to the West: Japanese Literature of the Modern Era. New York: Hold, Rinehart, and Winston, 1984. Pollack, David. Reading Against Culture: Ideology and Narrative in the Japanese Novel. Ithaca: Cornell University Press, 1992.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.